Editorial
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma
Renal cell carcinoma: complete response
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma
Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient